Physician profile
Beth M Silverstein
NPI 1013104660
$8,389.51
in general payments reported to CMS, 2019-2025
47 companies · $1,059 in 2025
The $1,059 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.68 · 2020: $351 · 2021: $2,004 · 2022: $1,798 · 2023: $2,579 · 2024: $581 · 2025: $1,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,199 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,199.45 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,002.75 | 2021-2025 | Qulipta, Botox, Ubrelvy |
| Biohaven Pharmaceuticals, INC. | $1,212.71 | 2020-2021 | |
| Pfizer INC. | $503.09 | 2023-2025 | |
| Allergan, INC. | $453.46 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $420.87 | 2022 | |
| Neurocrine Biosciences, INC. | $370.57 | 2022-2023 | Ingrezza, Ongentys |
| Argenx US, INC. | $258.71 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Lundbeck LLC | $257.90 | 2022-2025 | Vyepti |
| Sk Life Science, INC. | $218.85 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $206.99 | 2023 | Gammagard Liquid |
| Novartis Pharmaceuticals Corporation | $205.88 | 2021-2025 | |
| Amneal Pharmaceuticals LLC | $177.36 | 2020-2024 | Rytary, Crexont, Lyvispah |
| Teva Pharmaceuticals USA, INC. | $145.54 | 2020-2022 | |
| Currax Pharmaceuticals LLC | $134.17 | 2021-2023 | Onzetra Xsail |
| Harmony Biosciences LLC | $130.14 | 2022-2023 | Wakix |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $106.52 | 2024-2025 | Tremfya, Simponi Aria, Simponi |
| Almatica Pharma LLC | $94.68 | 2022-2023 | Gralise |
| Neurelis, INC. | $92.87 | 2021-2025 | Valtoco |
| Merz Pharmaceuticals, LLC | $92.33 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $90.58 | 2023 | Ztlido |
| Emd Serono, INC. | $86.59 | 2022-2023 | Mavenclad |
| Lilly USA, LLC | $70.11 | 2022-2023 | Reyvow, Emgality |
| Corium, LLC | $69.99 | 2023 | Adlarity |
| Grifols USA, LLC | $69.94 | 2022-2025 | Gamunex-C |
| Alexion Pharmaceuticals, INC. | $68.13 | 2023-2025 | Ultomiris |
| Medtronic, INC. | $62.55 | 2022-2023 | Percept PC Brainsense |
| Csl Behring | $62.23 | 2022-2024 | Kcentra |
| Tanabe Pharma America, INC. | $55.46 | 2022-2023 | |
| Acadia Pharmaceuticals INC | $54.79 | 2022-2023 | Nuplazid |
| Genzyme Corporation | $53.84 | 2021-2023 | |
| Ucb, INC. | $47.83 | 2023-2025 | Rystiggo |
| Kyowa Kirin, INC. | $47.43 | 2023 | Nourianz |
| Genentech USA, INC. | $47.32 | 2023 | Ocrevus |
| Biogen, INC. | $46.35 | 2023 | Vumerity, Spinraza |
| Alnylam Pharmaceuticals INC. | $46.08 | 2025 | Amvuttra |
| Amgen INC. | $40.78 | 2022-2023 | Aimovig |
| Horizon Therapeutics Plc | $38.19 | 2023 | Uplizna |
| Impel Pharmaceuticals INC. | $36.08 | 2022-2023 | Trudhesa |
| Grt US Holding, INC. | $35.82 | 2022 | |
| Boston Scientific Corporation | $32.83 | 2022 | |
| Merck Sharp & Dohme LLC | $28.89 | 2022-2023 | Belsomra |
| Avanir Pharmaceuticals, INC. | $24.67 | 2022 | |
| Janssen Pharmaceuticals, INC | $23.08 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $21.47 | 2023 | Firdapse |
| Medtronic USA, INC. | $16.68 | 2019 | |
| Upsher-Smith Laboratories LLC | $13.74 | 2022 | |
| Acorda Therapeutics, INC | $12.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Silverstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.